Skip to main content
Log in

Osteoporosediagnostik und -therapie bei über 65-Jährigen

Aktueller Stand und Zukunftsaussichten

Diagnostics and treatment of osteoporosis in patients over 65 years old

Current status and future perspectives

  • Themenschwerpunkt
  • Published:
Zeitschrift für Gerontologie und Geriatrie Aims and scope Submit manuscript

Zusammenfassung

Nur ein Drittel aller Frauen im Alter über 65 Jahren mit einer Osteoporose erhält eine Therapie; viele erleiden eine Fraktur. Bei Männern ist die Datenlage nicht klar. Mithilfe eines neu erarbeiteten Algorithmus und anhand der aktuellen Leitlinien sind die Diagnose und eine spezifische Therapie einfach zu vorzunehmen. Die Differenzialtherapie ist gemäß dem Nebenwirkungsprofil der spezifischen Medikation individuell zu wählen; die therapeutischen Effekte der spezifischen Osteoporosemedikation sind in den Vergleichsstudien nicht signifikant unterschiedlich. Der vorliegende Beitrag bietet eine aktuelle Übersicht über die derzeit verfügbare medikamentöse und nichtmedikamentöse Therapie und fasst Ansätze für eine verbesserte Kontrolle der Erkrankung mithilfe neuer Medikamente und Interventionen zusammen.

Abstract

Only one third of all women with osteoporosis over the age of 65 years are adequately treated; therefore, many experience fractures. For men the data are insufficient. Using a newly developed algorithm and based on the current guidelines, the diagnosis and specific treatment of osteoporosis can be easily set up. The differential treatment should be selected in an individualized approach based on the side effect profile of the specific medication. No statistically significant differences were found between most specific osteoporotic drugs in head-to-head comparisons. This article presents an overview of the currently available pharmaceutical and non-pharmaceutical forms of treatment as well as approaches with novel medications and interventions for a better control of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Hadji P, Klein S, Gothe H et al (2013) The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int 110(4):52–57

    PubMed  PubMed Central  Google Scholar 

  2. Siris ES, Yu J, Bognar K et al (2015) Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage. Clin Interv Aging 10:1813–1824

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Schray D, Neuerburg C, Stein J et al (2016) Value of a coordinated management of osteoporosis via Fracture Liaison Service for the treatment of orthogeriatric patients. Eur J Trauma Emerg Surg 42(5):559–564

    Article  CAS  PubMed  Google Scholar 

  4. Gamboa A, Duaso E, Marimón P et al (2018) Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit. Osteoporos Int. https://doi.org/10.1007/s00198-018-4622-6

    Article  PubMed  Google Scholar 

  5. Nayak S, Greenspan SL (2018) How Can We Improve Osteoporosis Care: A Systematic Review and Meta-Analysis of the Efficacy of Quality Improvement Strategies for Osteoporosis. J Bone Miner Res. https://doi.org/10.1002/jbmr.3437

    Article  PubMed  Google Scholar 

  6. Karjalainen JP, Riekkinen O, Töyräs J et al (2012) Multi-site bone ultrasound measurements in elderly women with and without previous hip fractures. Osteoporos Int 23(4):1287–1295

    Article  CAS  PubMed  Google Scholar 

  7. Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(4):392–396

    Article  CAS  PubMed  Google Scholar 

  8. Adler RA (2012) Secondary fracture prevention. Curr Osteoporos Rep 10(1):22–27

    Article  PubMed  Google Scholar 

  9. Baim S, Leslie WD (2012) Assessment of fracture risk. Curr Osteoporos Rep 10(1):28–41

    Article  PubMed  Google Scholar 

  10. Gosch M, Stumpf U, Kammerlander C, Böcker W, Heppner HJ, Wicklein S (2018) Management of osteoporosis after fragility fractures. Z Gerontol Geriatr 51(1):113–125

    Article  CAS  PubMed  Google Scholar 

  11. Dovjak P, Föger-Samwald U, Konrad M, Bichler B, Pietschmann P (2014) Secondary confounders of osteoporotic hip fractures in patients admitted to a geriatric acute care department. Z Gerontol Geriatr. https://doi.org/10.1007/s00391-014-0821-8

    Article  PubMed  Google Scholar 

  12. Adler RA (2012) Laboratory testing for secondary osteoporosis evaluation. Clin Biochem 45(12):894–900

    Article  CAS  PubMed  Google Scholar 

  13. Bogoch ER, Elliot-Gibson V, Wang RY, Josse RG (2012) Secondary causes of osteoporosis in fracture patients. J Orthop Trauma 26(9):e145–152

    Article  PubMed  Google Scholar 

  14. Bours SP, van Geel TA, Geusens PP et al (2011) Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab 96(5):1360–1367

    Article  CAS  PubMed  Google Scholar 

  15. Prophylaxe DVO Diagnostik und Therapie der Osteoporose. In. https://www.dv-osteologie.org/uploads/Leitlinie%202017/Finale%20Version%20Leitlinie%20Osteoporose%202017_end.pdf 2017

    Google Scholar 

  16. Langdahl BL, Andersen JD (2018) Treatment of Osteoporosis: Unmet Needs and Emerging Solutions. J Bone Metab 25(3):133–140

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cakir B, Odabasi E, Turan M, Guler S, Kutlu M (2002) Secondary osteoporosis in women. A retrospective analysis. Arch Gynecol Obstet 266(4):214–217

    Article  CAS  PubMed  Google Scholar 

  18. Pietschmann P, Rauner M, Sipos W, Osteoporosis K‑SK (2009) an age-related and gender-specific disease—a mini-review. Gerontology 55(1):3–12

    Article  PubMed  Google Scholar 

  19. Avenell A, Mak JC, O’Connell D (2014) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 4:CD227

    Google Scholar 

  20. Black DM, Postmenopausal Osteoporosis RCJ (2016) N Engl J Med 374(21):2096–2097

    PubMed  Google Scholar 

  21. Bolland MJ, Grey A, Reid IR (2015) Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis? Climacteric 18(Suppl 2):22–31

    Article  PubMed  Google Scholar 

  22. Albert SG, Reddy S (2017) CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS. Endocr Pract 23(7):841–856

    Article  PubMed  Google Scholar 

  23. Eriksen EF, Lyles KW, Colón-Emeric CS et al (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg 45(9:1493–1502

    Article  Google Scholar 

  25. Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. (2018) J Bone Miner Res 33(2):190–198

    Article  CAS  PubMed  Google Scholar 

  26. Rachner TD, Hofbauer L, Göbel A, Tsourdi E (2018) Novel therapies in osteoporosis: PTH-related peptide analogues and inhibitors of sclerostin. J Mol Endocrinol. https://doi.org/10.1530/JME-18-0173

    Article  Google Scholar 

  27. Ensrud KE, Osteoporosis CCJ (2017) Ann Intern Med 167(3):ITC17–ITC32

    Article  PubMed  Google Scholar 

  28. Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H (2013) Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 28(1):196–205

    Article  CAS  PubMed  Google Scholar 

  29. Tsai JN, Uihlein AV, Burnett-Bowie SM et al (2016) Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metab 101(5):2023–2030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57

    Article  CAS  PubMed  Google Scholar 

  31. Karjalainen JP, Riekkinen O, Kröger H (2018) Pulse-echo ultrasound method for detection of post-menopausal women with osteoporotic BMD. Osteoporos Int. https://doi.org/10.1007/s00198-018-4408-x

    Article  PubMed  Google Scholar 

  32. Schousboe JT, Riekkinen O, Karjalainen J (2017) Prediction of hip osteoporosis by DXA using a novel pulse-echo ultrasound device. Osteoporos Int 28(1):85–93

    Article  CAS  PubMed  Google Scholar 

  33. Eccles E, Thompson JD, Roddam H (2018) An evaluation of Fracture Liaison Services in the detection and management of osteoporotic fragility fractures: A narrative review. Radiography (Lond) 24(4):392–395

    Article  CAS  Google Scholar 

  34. Gosch M, Druml T, Nicholas JA et al (2015) Fragility non-hip fracture patients are at risk. Arch Orthop Trauma Surg 135(1):69–77

    Article  CAS  PubMed  Google Scholar 

  35. Rachner TD, Khosla S, Osteoporosis HLC (2011) now and the future. Lancet 377(9773):1276–1287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. https://doi.org/10.1056/NEJMoa1607948

    Article  PubMed  Google Scholar 

  37. Lewiecki EM, Dinavahi RV, Lazaretti-Castro M et al (2018) One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. https://doi.org/10.0002/jbmr.3622

    Article  PubMed  Google Scholar 

  38. Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585–1594

    Article  CAS  PubMed  Google Scholar 

  39. Fares A (2018) Pharmacological and Non-pharmacological Means for Prevention of Fractures among Elderly. Int J Prev Med 9:78

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter Dovjak.

Ethics declarations

Interessenkonflikt

P. Dovjak gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dovjak, P. Osteoporosediagnostik und -therapie bei über 65-Jährigen. Z Gerontol Geriat 52, 421–427 (2019). https://doi.org/10.1007/s00391-019-01548-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00391-019-01548-w

Schlüsselwörter

Keywords

Navigation